A fingerprint of the ‘metabolome’, documenting all metabolites from metabolic processes in an individual’s cells, tissues and organs, provides us with the most accurate assessment of the biological state of that individual. As such, in-depth assessment of the metabolome by means of ‘metabolomics’ provides a very powerful tool to study physiological as well as pathophysiological conditions. In a laboratory setting, mass spectrometry (MS) is the most favored tool for metabolomics, but in a more practical and/or clinical setting the use of MS-based applications is not that straightforward. Nevertheless, the introduction of Rapid Evaporative Ionisation MS (REIMS) offers compelling perspectives as REIMS can significantly reduce time and workload, but enhance research output and efficiency by eliminating sample preparation steps. In light of this, Prof. Lynn Vanhaecke and 19 co-supervisors wish to purchase the required infrastructure to develop a multi-matrix REIMS platform for ‘metabolomics in health and disease’ as this will enable the rapid on site or point of care translatable diagnosis, prognosis and prediction of a variety of in vitro and in vivo (patho)physiological changes in a large spectrum of matrices. In doing so, Ghent University would be the first Belgian and one of the first European institutes to house the REIMS platform, serving the consortium members, external partners as well as the wider scientific community.